Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 28, 2015; 21(16): 4779-4787
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.4779
Published online Apr 28, 2015. doi: 10.3748/wjg.v21.i16.4779
Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease
Raghavan Chinnadurai, Spencer Ng, Vijayakumar Velu, Jacques Galipeau, Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, United States
Vijayakumar Velu, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, United States
Jacques Galipeau, Department of Pediatrics, Emory University, Atlanta, GA 30322, United States
Author contributions: Chinnadurai R, Ng S, Velu V and Galipeau J contributed to writing, figure design, editing and revising of this manuscript.
Conflict-of-interest: Raghavan Chinnadurai, Spencer Ng, Vijayakumar Velu, and Jacques Galipeau have no conflict of interest to disclose.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Jacques Galipeau, Professor, Department of Hematology and Oncology, Winship Cancer Institute, Emory University, 1365-C Clifton Road NE, Atlanta, GA 30322, United States. jgalipe@emory.edu
Telephone: +1-404-7781779 Fax: +1-404-7783965
Received: December 8, 2014
Peer-review started: December 9, 2014
First decision: January 22, 2015
Revised: February 13, 2015
Accepted: March 27, 2015
Article in press: March 27, 2015
Published online: April 28, 2015
Peer-review started: December 9, 2014
First decision: January 22, 2015
Revised: February 13, 2015
Accepted: March 27, 2015
Article in press: March 27, 2015
Published online: April 28, 2015
Core Tip
Core tip: Several clinical trials have investigated the use of mesenchymal stromal cells (MSCs) for the treatment of inflammatory bowel disease. Although MSC therapy has proven to be safe, efficacy remains to be determined. Animal model studies are necessary to evaluate the efficacy and mechanism of action of MSCs, which will improve ongoing clinical trials. However, clinical translation is largely hampered by (1) variability of colitis animal models available; and (2) differences in the biology of murine and human MSC counterparts. Here we discuss the challenges and approaches of translating animal studies to clinical trials.